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Decreased sensitivity to paroxetine-induced inhibition of
peripheral blood mononuclear cell growth in depressed and
antidepressant treatment-resistant patients
S Rzezniczek1, M Obuchowicz1, W Datka2, M Siwek2, D Dudek2, K Kmiotek2, K Oved3,4, N Shomron4,5, D Gurwitz3,5 and A Pilc1,6
Major depression disorder (MDD) is the most widespread mental disorder. Selective serotonin reuptake inhibitors (SSRIs) are used
as first-line MDD treatment but are effective in o70% of patients. Thus, biomarkers for the early identification of treatment-
resistant (TR) MDD patients are needed for prioritizing them for alternative therapeutics. SSRI-induced inhibition of the growth of
peripheral blood mononuclear cells (PBMCs) is mediated via their target, the serotonin transporter (SERT). Here, we examined
whether antidepressant drug-induced inhibition of the growth of PBMCs differed between MDD patients and healthy controls.
PBMCs from well-characterized 33 treatment-sensitive (TS) and 33 TR MDD patients, and 24 healthy volunteers were studied.
Dose-dependent inhibition of PBMCs growth was observed for both the non-SSRI antidepressant mirtazapine and the SSRI
antidepressant paroxetine. Significantly lower sensitivities to 20 μM paroxetine were observed in MDD compared with control
PBMCs prior to treatment onset (13% and 46%, respectively; Po0.05). Following antidepressant drug treatment for 4 or 7 weeks,
the ex vivo paroxetine sensitivity increased to control levels in PBMCs from TS but not from TR MDD patients. This suggests that the
low ex vivo paroxetine sensitivity phenotype reflects a state marker of depression. A significantly lower expression of integrin beta-3
(ITGB3), a co-factor of the SERT, was observed in the PBMCs of MDD patients prior to treatment onset compared with healthy
controls, and may explain their lower paroxetine sensitivity. Further studies with larger cohorts are required for clarifying the
potential of reduced PBMCs paroxetine sensitivity and lower ITGB3 expression as MDD biomarkers.
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INTRODUCTION
Major depressive disorder (MDD) is among the most common
chronic human diseases with an estimated 350 million people of
all ages affected globally.1 Selective serotonin reuptake inhibitors
(SSRIs) are most commonly employed as a first-line treatment for
MDD. However, treatment resistance occurs in 430% of MDD
patients and this outcome requires alternative antidepressants.2,3
Typically, 2–4 weeks are required to evaluate the response to
antidepressants, and the clinical guidelines accordingly recom-
mend waiting for at least 4–8 weeks before switching to another
antidepressant drug when favorable response is not achieved. This
long waiting period, combined with the high rate of SSRI non-
response, increase adverse effect and suicide risks and contribute
to the high societal cost of MDD.4 Therefore, an unmet need to
identify treatment resistance biomarkers, preferably in the blood
(blood cells, plasma or serum), which will enable the early
identification of MDD patients who are likely to be resistant to
treatment with SSRI antidepressants exists. Such a biomarker
would also allow for the prioritization of these patients for
treatment with alternative antidepressant drugs and more
intensive clinical follow-up.
Circulating human lymphocytes express functional serotonin
transporter (SERT; encoded by SLC6A4)5–8 that exhibits a
pharmacology similar to those of the brain and platelet
SERTs9,10 and may therefore serve as an important means to
understand the mode of action of antidepressant drugs and
treatment resistance in MDD. Human lymphocyte SERT is
significantly reduced in MDD patients compared with healthy
controls.6,711 Furthermore, the SSRI drug fluoxetine significantly
increases the number of lymphocytes that express SERT.12 In
addition, the non-SSRI antidepressant drug mirtazapine exhibits a
similar effect on SERT expression, indicating that a complex
mechanism that is not directly related to SERT inhibition but may
possibly be related to lymphocyte growth inhibition may be
functioning.7,13
Recently, Morag et al.14 reported preliminary observations
regarding candidate SSRI response biomarker genes which were
detected with genome-wide expression profiling in human
lymphoblastoid cell lines (LCLs) from unrelated healthy donors
with relatively high or low sensitivities to growth inhibition by the
SSRI drug paroxetine. Epstein-Barr virus-immortalized human LCLs
are generated from peripheral blood B lymphocytes, retain
most of the phenotypic properties of B lymphocytes and
exhibit heterogeneity that is specific to the individuals from
whom the cells originated.14,15 Thus, human LCLs are suitable for
molecular and functional studies and for searching for drug
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response biomarkers.14–18 SSRI antidepressants, such as parox-
etine, fluoxetine, fluvoxamine and citalopram, as well as the
tricyclic antidepressant drugs amitriptyline and imipramine have
been demonstrated to dose-dependently inhibit the growth of
LCLs.15 Using a whole-genome expression microarray assay, a 36-
fold greater expression of Close Homolog of LCAM-1 (CHL1) was
observed in LCLs that exhibit lower SSRI sensitivity in vitro.14 The
CHL1 gene is located at 3p26.3 and encodes a cell adhesion
molecule that is classified as an L-CAM family member. Recent
studies have suggested a key role of CHL1 in integrin-mediated
embryonic neuronal cell migration.19–21 CHL1 is specifically
expressed in a subpopulation of central and peripheral neurons
and glia.22 In a subsequent work, Oved et al.17 demonstrated that
chronic treatment of LCLs with paroxetine (1 μM, 21 d) increases
the expression of Integrin beta-3 (ITGB3; also known as platelet
glycoprotein IIIa and CD61), which is a cell adhesion protein that is
required for SERT activity.23,24 The same treatment did not affect
CHL1 expression, and the authors have suggested that the cell
adhesion proteins CHL1 and ITGB3 interact in the cell
membrane.17 It was postulated that the expression levels of both
CHL1 and ITGB3 may serve as potential SSRI antidepressant
response biomarkers.17 Indeed, a recent study employing three
independent MDD cohorts has reported that certain CHL1 and
ITGB3 alleles may predict treatment resistance in MDD patients.25
The aim of the current study was to explore whether
mirtazapine- and paroxetine-mediated growth inhibition of
peripheral blood mononuclear cells (PBMCs), which include
lymphocytes, monocytes and macrophages, differ between
healthy volunteers and MDD patients and between treatment-
resistant (TR) and treatment-sensitive (TS) patients. The study also
explored whether the candidate biomarker genes CHL1 and ITGB3
are differentially expressed in PBMCs from TS and TR MDD
patients at the beginning of the study.
MATERIALS AND METHODS
Study participants
Blood samples were obtained from 66 clinically well-characterized MDD
patients, including 33 TS patients and 33 TR patients, as well as 24 age-
matched healthy volunteers. Blood samples from the TS patients were
collected three times: at the beginning of the study (TS I); after 4 weeks of
treatment (TS II); and after 7 weeks of treatment (TS III). The Hamilton and
Montgomery–Asberg Depression Rating Scale (MADRS) scores were
determined at the same time points.
Patient recruitment
Patients (55 women (83.3%) and 11 men (16.7%) above 18 years of age
(mean age, 46.7 ± 11.3 years)) who were admitted to the Department of
Psychiatry at Collegium Medicum Jagiellonian University who met the
DSM-IV criteria for major depression were enrolled. The studied population
included patients with diagnosis of a first or recurrent major depressive
episode. All patients demonstrated a current depressive episode. The
patients received standard antidepressant therapy with venlafaxine,
sertraline, escitalopram, paroxetine, fluoxetine or mirtazapine. The
depressive patients were divided into two groups, that is, a treatment-
sensitive (TS) and a treatment-resistant (TR) group. A TR episode was
defined as a lack of remission (⩽7 points change on the 17-item Hamilton
Depression scale) following a minimum of two courses of adequate
antidepressant treatment (⩾4 weeks at an adequate dose). Exclusion
criteria included the presence of severe and chronic medical and
neurological diseases including migraine, epilepsy, Parkinson’s disease,
Alzheimer’s disease, multiple sclerosis, stroke, transient ischemic attack,
cerebral palsy and mental retardation, and the presence of profound
personality disorders, including borderline, antisocial, narcissistic and
paranoid personality disorders. The Hamilton Depression Rating Scale
(HDRS, 17 items), the Clinical Global Impression scale (CGI) and the MADRS
were used for assessing the efficacy of the antidepressant therapy, and
patient status was evaluated before treatment and 1, 4 and 7 weeks after
the initiation of treatment. Therapeutic responses were defined as ‘much
improved’ or ‘very much improved’ based on the CGI scale along with a
reduction of at least 50% on the MADRS (MADRS/CGI criteria) score or
HADRS score (HADRS/CGI criteria). Remission was defined as ‘very much
improved’ based on the CGI scale along with a score ⩽ 10 on the MADRS
(MADRS/CGI criteria), a HADRS score (HADRS/CGI criteria) ⩽ 7 or a BDI score
(BDI/CGI criteria) ⩽ 9. After the examination, venous blood was drawn. The
study was approved by the Ethical Committee of Collegium Medicum
Jagiellonian University Kraków, and informed consent was obtained from
all participants.
PBMC isolation
Peripheral blood was collected in K3EDTA collecting tubes (Sarstedt,
Nümbrecht, Germany). The tubes were immediately transported to a
laboratory for PBMC isolation. The lymphocytes were isolated with a Ficoll
gradient (Lymphocyte Separation Medium, Lonza, Basel, Switzerland) using
tubes with separation filters (BD, Franklin Lakes, NJ, USA). The PBMC layer
was washed twice with PBS (Lonza), and the cells were counted and then
diluted with RPMI-1640 supplemented with 10% heat-inactivated fetal
bovine serum, 1% penicillin/streptomycin and 2 μM extra L-glutamine
(Lonza).
Drugs and PBMC cultures
Paroxetine (Sigma Aldrich, St. Louis, MO, USA) was dissolved in PBS at a
concentration of 1 mM. PBMCs were incubated with several paroxetine
concentrations (while maintaining the final PBS concentration in the
medium at 4%). The cells were seeded on 96-well plates at a concentration
of 2 × 105 cells per well. Each drug concentration was assayed in triplicate.
The PBMCs were incubated at 37 °C in 5% CO2 and 100% humidity and
cultured for 72 h.
WST-1 proliferation assay
The viability of the cells was examined using the WST-1 proliferation assay
(Roche, Basel, Switzerland). This assay is based on the measurement of
biochemical activity relative to cellular respiratory processes. A substrate
(tetrazole salt) is biotransformed by mitochondrial dehydrogenase into
soluble formazan and its concentrations then measured spectrophotome-
trically at 450 nm. Next, 5 μl of the WST-1 solution was dispensed into each
cell culture well. The plates were incubated for 2 h at 37 °C. The
absorbance at 450 nm was measured using a BioTek Synergy multiplate
reader (BioTek, Winooski, VT, USA). The obtained results were normalized
to measurements from non-treated cells and are represented as the
percent growth inhibition. The drug IC50 values were calculated for the
healthy donors using GraphPad Prism (GraphPad Software, La Jolla, CA,
USA), by plotting the percent viability against the drug concentration and
fitting the curve using an allosteric sigmoidal model. The PBMC-growth
inhibition was calculated at the determined IC50 concentration using an
allosteric sigmoidal curve fit. One-way analysis of variance (ANOVA) with
Tukey post hoc and t-tests were used for determining the significance of
differences between groups.
RNA extraction and cDNA synthesis
Total RNA was extracted from each PBMC sample using the spin column
method (RNeasy; QIAGEN, Hilden, Germany). RNA quality and quantity
were checked using a NanoDrop Spectrophotometer (NanoDrop 1000,
Wilmington, DE, USA) and electrophoresis in Agarose gel. One microgram
of RNA was digested with gDNA Wipeout Buffer for removing genomic
DNA contamination. cDNA was synthesized from RNA using the reverse
transcription method (QuantiTect Reverse Transcription Kit; QIAGEN) with
random oligo-dT primers.
Quantitative real-time PCR
CHL1. Gene expression was determined using real-time PCR (CFX96
Touch, Bio-Rad, Hercules, CA, USA) performed with the SybrGreen I assay
(Applied Biosystems, Carlsbad, CA, USA). For each reaction, 100 ng of cDNA
was used. The ACTβ and GUSB genes were selected as reference genes. The
temperature conditions for quantitative real-time PCR (qRT-PCR) were as
follows:
● CHL1: 95 °C for 10 min, (95 °C for 15 s, 59.9 °C for 30 s, 72 °C for 25 s) × 55
cycles, melting analysis
● ACTβ and GUSB: 95 °C for 10 min, (95 °C for 15 s, 64 °C for 30 s) × 45
cycles, melting analysis
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● The individual forward and reverse primers used were:
Gene Seq. forward Seq. reverse
CHL1 5ʹ-AAGGACAGTCGCAATGACTAC-3ʹ 5ʹ-ATTGAAGACTCACTGCCACTC-3ʹ
GUSB (control) 5ʹ-TCACCACCAGCGTGGAGCAA-3ʹ 5ʹ-TAGGCAGGGCGTTCGTGCAT-3ʹ
The GUSB gene was selected as a reference gene due to its stable
expression compared with ACTβ.17 Standards and melting curves were
used to control the efficiency and quality of the PCR reaction. Data
analyses based on the ΔΔCt method and Bio-Rad CFX Manager software
(Bio-Rad) were employed for the normalized gene study.
ITGB3. Real-time PCR assays were performed using TaqMan (TaqMan,
Applied Biosystems) probe-based gene expression analysis for one
selected gene, that is, human ITGB3, and one control gene, that is, human
GUSB. The real-time PCR experiments were conducted with mixtures (20 μl
final volume) containing 50 ng of cDNA template, 2 × Thermo Scientific
Absolute Blue QPCR ROX Mix and 20 × Solaris quantitative PCR gene
expression assays (Thermo Scientific, Carlsbad, CA, USA) with GUSB
employed as a control gene. The PCR reactions were performed using
an ABI STEP ONE Sequence Detection System (Applied Biosystems), and
the cycle conditions were as follows: 50 °C for 2 min; 95 °C for 15 min; and
40 cycles of 95 °C for 15 s and 60 °C for 1 min.
The individual forward and reverse primers used were:






Characteristics of the study population
The sociodemographic and clinical features of the study sample
are provided in Table 1. The mean age of TS and TR MDD patients
did not differ (48.4 ± 10.9 years vs 45.1 ± 12.3 years; P= 0.26); no
significant differences in the male/female ratios of the TS and TR
MDD patients (4/29 and 7/26, respectively) were observed.
While there were no significant between-group distinctions
related to employment status, education and smoking, the
patients with TR depression were more likely to have no partner,
which agrees with earlier observations.26 In addition, these
patients had suffered more relapses and were at a higher risk of
hospitalization (Table 1).
The MADRS scores of the patients before and following treatment
The MADRS scores for the patients of the TS I, TS II, TS III and TR
groups are depicted in Figure 1a, and significant improvements
following 4 and 7 weeks of antidepressant drug treatment were
observed. Only patients who completed the 7-week treatment
and donated blood samples three times were included.
The influence of paroxetine on PBMC viability
Paroxetine inhibited PBMC growth in a dose-dependent manner
with an IC50 of 20 μM± 7.6 (Figure 1b). In the healthy control
population, 20 μM paroxetine inhibited the growth of PBMCs
by 46 ± 32%. In the TS I, TS II, TS III and TR groups, the mean
growth inhibition values were 13 ± 18%, 56 ± 33%, 62 ± 33%
and 14 ± 16%, respectively (Figure 2). Significant differences in
paroxetine growth inhibition sensitivity levels were noted
between healthy and TS I groups, and healthy and TR groups
(Po0.05; Kruskal–Wallis test and Dunn's multiple comparison test,
F = 23.07).
CHL1 and ITGB3 gene expression in MDD and control PBMCs
The CHL1 gene expression level was quantified to evaluate its
potential as a putative SSRI response biomarker. No significant
differences in CHL1 gene expression between investigated groups
were observed (Figure 3).
Table 1. Sociodemographic and clinical characteristics of the study participants
TS and TR TS only TR only Comparison TS vs TR (statistics)
Mean age (± s.d.) 46.7±11.3 45.1± 12.3 48.4± 10.9 P40.05 (t-test)
Sex
Male 11(16.7%) 4 (12.1%) 7 (23.2%) P40.05 (Χ2-test)
Female 55 (83.3%) 29 (87.9%) 26 (78.8%)
Employment status
Employed 14 (21.3%) 9 (27.3%) 5 (15.1%) Po0.05 (Χ2-test)
Unemployed 28 (42.3%) 18 (54.5%) 10 (30.3%)
Annuitant 24 (36.4%) 6 (18.2%) 18 (54.5%)
Education
Primary 4 (6%) 4 (12.2%) 0 P40.05 (Χ2-test)
Secondary 36 (54.6%) 16 (48.4%) 20 (60.6%)
Higher 26 (39.4%) 13 (39.4) 13 (39.4%)
Marital status
Single 48 (72.7%) 20 (60.6%) 28 (84.8%) Po0.05 (Χ2-test)
Married 18 (27.3%) 13 (39.4%) 5 (15.2%)
Smoking
Non-smokers 39 (59.1%) 19 (57.6%) 20 (60.6%) P40.05 (Χ2-test)
Smoking o20 cigarettes daily 13 (19.7%) 8 (24.2%) 5 (15.1%)
Smoking 420 cigarettes daily 14 (21.2%) 6 (18.2%) 8 (24.3%)
Mean number of hospitalizations (± s.d.) 2.71±3.52 1.03± 2.21 4.51± 3.75 Po0.01 (Mann–Whitney U-test)
Mean number of relapses (± s.d.) 1.71±1.04 1.36± 0.74 2.09± 1.18 Po0.05 (Mann–Whitney U-test)
Abbreviations: TR, treatment resistant; TS, treatment sensitive. Po0.05 denotes statistical significance.
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We observed significantly reduced ITGB3 expression levels in
the PBMCs of the MDD patients compared with the healthy group
(fold-difference: 0.45, P= 0.0011; Figure 4a). Significantly reduced
ITGB3 expression levels were observed for the TR MDD patients
compared with the control group (fold-difference: 0.45, one-way
ANOVA, P= 0.003). In addition, a trend of reduced ITGB3
expression was observed for the TS MDD group compared
with the control group (fold-difference: 0.46, one-way ANOVA,
P= 0.0712; Figure 4b).
Figure 1. (a) The MADRs scores of the MDD patients in the TS I, TS II,
TS III and TR groups. Only the patients who completed the entire 7-
week course of treatment and donated blood three times were
analyzed (significant differences were noted in the comparisons of
the TS I group with the TS II and TS III groups and the comparisons
of the TS II and TS III groups with the TR group; one-way ANOVA and
Tukey post hoc tests, *Po0.05). (b) Paroxetine-mediated growth
inhibition in PBMCs from a healthy donor (see Materials and
methods for experimental protocol). The experiment was repeated
three times. ANOVA, analysis of variance; MADR, Montgomery–
Asberg Depression Rating Scale; MDD, major depression disorder;
PBMC, peripheral blood mononuclear cell; TR, treatment resistant;
TS, treatment sensitive.
Figure 2. Inhibition of PBMC growth by 20 μM paroxetine in the
healthy controls vs the TS I, TS II, TS III and TR MDD patients. The
inhibition values for the PBMC samples from individual control and
MDD patients are displayed. The lines indicate the mean values.
MDD, major depression disorder; PBMC, peripheral blood mono-
nuclear cell; TR, treatment resistant; TS, treatment sensitive.
Figure 3. Real-time PCR measurement of CHL1 expression in the
PBMCs of the healthy controls and the two MDD groups. H, healthy
volunteers; MDD, major depression disorder; PBMC, peripheral
blood mononuclear cell; TR, treatment resistant; TS, treatment
sensitive.
Figure 4. (a and b) Real-time PCR measurement of ITGB3 expression
in the PBMCs of the (a) healthy controls (H) and the MDD patients
before treatment onset (TR+TS groups combined) and (b) in the
healthy controls, TR and TS MDD patients. The results are expressed
as fold-changes± s.e.m. for the comparisons of each group with the
healthy group. **Po0.005. P-values were calculated as follows: (i)
Student’s t-test for independent samples. (ii) One-way ANOVA with
Bonferroni correction. ANOVA, analysis of variance; H, healthy
volunteers; MDD, major depression disorder; PBMC, peripheral
blood mononuclear cell; TR, treatment resistant; TS, treatment
sensitive.
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Our findings are summarized in Supplementary Table S1. The
methodology and results related to the inhibitory effects of
mirtazapine are described in the Supplementary File.
DISCUSSION
During the past three decades, SSRI antidepressant drugs remain
the first-line treatment for MDD. Yet, over 30% of MDD patients do
not respond adequately to SSRI drug treatment and require
alternative antidepressants, a process that may take many weeks
and adds to the high morbidity and societal costs of MDD. Our
study explored the potential of both phenotypic (in vitro SSRI
sensitivity) and genomic (gene expression) measurements in
PBMCs of MDD patients as potential trait and state MDD
biomarkers.
Studying the influence of SSRI drugs on the growth and survival
of human PBMCs is possible due to the presence of functional
SERT in lymphocytes; this SERT exhibits a pharmacology that is
similar to that of the SERTs in neuronal tissues and blood
platelets.9 We observed that both the SSRI antidepressant
paroxetine and the non-SSRI antidepressant mirtazapine inhibited
PBMC growth in concentration-dependent manners (Figure 1b
and Supplementay Figure 1S). Our findings from the PBMCs of
healthy donors are closely similar to those obtained with LCLs by
Morag et al. in ref. 14. The twofold greater paroxetine IC50 values
of the PBMCs compared with the LCLs could reflect the fact that
LCLs, unlike PBMCs, continue to proliferate in vitro and are
therefore more sensitive to cell proliferation inhibitors. In addition,
LCLs are generated from B lymphocytes, whereas PBMCs also
include T-lymphocytes, monocytes and macrophages, which may
also differentially affect drug-mediated growth modulation
compared with LCLs.
Only a few studies by other groups have examined growth
inhibition of LCLs in studies of central nervous system drugs such
as lithium.27 The drug applied in our studies was the SSRI
antidepressant paroxetine.28 A large spectrum of sensitivities to
cell growth inhibition by paroxetine have been described in
individual LCLs.14,15 Our exploration of 20 μM paroxetine-mediated
growth inhibition phenotypes in healthy control PBMCs revealed a
large sensitivity spectrum (from full to no inhibition; Figure 2 and
Supplementary Figure S3A). Among the untreated MDD patients
TS I and TR, a marked significant decrease in the average
sensitivity to paroxetine was observed (Figure 2 and
Supplementary Figures S3B and C). In the group of 30 TS I MDD
patients, only 2 patients displayed 450% growth inhibition by
20 μM paroxetine, and in the TR MDD group only a single patient
exhibited similar finding. The opposite was observed in the TS II
and TS III MDD groups, that is, a restoration of higher paroxetine
sensitivity was observed: only 3 of 16 (19%) and 2 of 8 (25%)
patients in these respective groups displayed o20% sensitivity
toward 20 μM paroxetine (Supplementary Figures S4A and B).
Thus, we observed that among the TS MDD patients following
treatment (TS II and TS III groups), the sensitivity of the PBMCs to
paroxetine-induced growth inhibition was restored in the majority
of MDD patients to a level that closely resembled that of healthy
control PBMCs (Figure 2), which sharply contrasts with our
observations for PBMC-growth inhibition by the non-SSRI drug
mirtazapine (Supplementary Figure S2).
For many years, attempts to identify trait and state biomarkers
of affective disorders and for SSRI antidepressant response have
met with little success. This task is difficult due to the multifactorial
background of affective disorders. The perfect trait biomarker
would be easily accessible, disorder-specific and constantly
present (that is, independent of the symptomatic status of the
patient). In contrast, an ideal state biomarker would reflect the
specific phase of the disorder. Therefore, the identification of both
trait and state biomarkers for affective disorders would represent
significant achievement with far-reaching clinical, as well as
scientific consequences, as such biomarkers would allow for better
understanding of the etiological and pathophysiological correlates
of affective disorders.29 The restoration of the lower sensitivity of
the PMBCs from the TS MDD patients to the higher paroxetine-
induced growth inhibition of healthy controls suggests that PBMC
paroxetine sensitivity reflects a state biomarker of depression.
Both the candidate gene approach, which has, for many years,
been focused on serotonin-related genes, and genome-wide
association studies, which have employed SNP arrays, have been
disappointing in terms of identifying antidepressant response
biomarkers for personalized MDD treatment.30 An alternative
approach, that is, genome-wide expression profiling as applied by
Morag et al.14 and Oved et al.,17 has led to the identification of two
brain-expressed cell adhesion protein-coding genes that are
implicated in neurogenesis and synaptogenesis, that is, CHL1
and ITGB3.
Expression levels of these genes in blood lymphocytes or
lymphocyte-derived LCLs have been suggested as tentative
biomarkers for predicting SSRI responses in MDD. Morag et al.14
reported a highly significant difference in CHl1 gene expression
between cell lines with low and high paroxetine sensitivities;
however, we observed no differences in CHL1 PBMC expression
levels between the investigated groups. A recent CHL1 genotyping
study revealed associations of the rs9841789 polymorphism and
its TT variant with low CHL1 expression and high sensitivity to
paroxetine.25 Furthermore, SNP marker analysis of a large
European sample revealed a significant influence of rs2133402
alleles on drug response and remission. Treatment responses were
found to be more common in patients with the G allele, and allele
T was clearly more common in the non-remission patients.25
ITGB3 codes for a cell adhesion protein that is of particular
interest as it is essential for the activity of SERT.23,24 Reduction of
the efficiency of ITGB3 or the deletion of a single ITGB3 allele may
result in a decrement of SERT efficacy.24,31 The paroxetine-
mediated inhibition of PBMC growth apparently depends on the
presence of functional SERT because robust correlations of growth
inhibition of LCLs from unrelated donors by different SSRIs have
been observed.13 A significant reduction in SERT expression in the
lymphocytes of MDD patients has been demonstrated,6,7,11 which
may explain the PBMC group differences in paroxetine sensitivities
observed in our current study. Moreover, chronic fluoxetine
treatment has been demonstrated to increase the number of
lymphocytes expressing SERT,12 which may, in part, explain the
restoration of PBMC drug sensitivity observed in the majority of
our TS MDD patients.
In the TR MDD patients, paroxetine inhibited PBMC growth to a
lower extent. It is plausible that SSRI antidepressants are less
effective in TR MDD patients because the expression and/or
functionality of the SERT remains low, possibly due to the reduced
expression of ITGB3 indicated by our results (Figure 4b). The lower
ITGB3 expression observed here in MDD compared with control
PBMCs is of particular interest because chronic (21 days)
paroxetine treatment of LCLs has been demonstrated to increase
the ITGB3 expression by nearly twofold.17 Further investigation of
PBMC gene expression levels following antidepressant treatment
in different MDD patient groups is vital for uncovering the role of
ITGB3 in the mode of action of SSRI antidepressants and the utility
of PBMC ITGB3 expression level as a MDD biomarker. The
placement of our results in the context of the ITGB3/CHL1/SERT
hypothesis described by Oved et al. in ref. 17 remains speculative
and requires further investigation.
Study limitations
The present study has several limitations. The MDD patients were
treated during all stages of our study while they were taking
additional antidepressant medications. Moreover, drug wash-out
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period was excluded due to the lack of ethical committee
approval.
Future studies with larger cohorts are required to validate our
current observations and should include measurements of the
expression levels of additional genes and regulatory microRNAs,
whose products have been implicated in the SSRI pathway, such
as SLC6A4, miR-221 and miR-222.17
CONCLUSION
The restoration of the sensitivity of the PMBCs from the TS MDD
patients to paroxetine-induced growth inhibition may indicate
that the paroxetine sensitivity of PBMCs reflects a state marker of
depression. This notion is further supported by our finding that
the inhibition of growth by paroxetine in the vast majority of the
patients in the TR MDD group (32 out of 34) remained at the same
low level observed in the untreated MDD patients. The lower
ITGB3 expression level observed in the PBMCs obtained from the
MDD patients is noteworthy, and suggests that increased ITGB3
expression on chronic SSRI treatment plays a role in the
therapeutic action of these drugs in MDD.17 Further studies with
larger patient cohorts are required to clarify the potential role of
reduced PMBC SSRI sensitivity as an informative biomarker for
TR MDD.
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